Increasing chemotherapy dose density and intensity: Phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma

Oncologist

Volumn 10, Issue 2, 2005, Pages 138-149

  Blayney, Douglas W ^a,d   McGuire, Brian W ^b   Cruickshank, Scott E ^b   Johnson, David H ^c  

^a Wilshire Oncol Medical Group Inc   (United States)

^b AMGEN INC   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Chemotherapy; Drug dose response relationships; Filgrastim; Neutropenia; Non Hodgkin's lymphoma; Non small cell lung carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOPULMONARY ARREST; CAUSE OF DEATH; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DYSPNEA; FATIGUE; FEMALE; FEVER; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOBLASTIC LYMPHOMA; LUNG ABSCESS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; SEPSIS; SOMNOLENCE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; FILGRASTIM; HUMANS; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PREDNISONE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VINCRISTINE;

EID: 13844312616     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-2-138     Document Type: Article

References (25)

1. Frei E 3rd, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980;69:585-594.
2. Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987;14:65-74.
3. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990;8:1935-1937.
4. Longo DL, Duffey PL, DeVita VT Jr et al. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 1991;9:2042-2051.
5. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997;24(suppl 10):S10-3-S10-10.
6. Epelbaum R, Faraggi D, Ben-Arie Y et al. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 1990;66:1124-1129.
7. Kwak LW, Halpern J, Olshen RA et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-977.
8. Lepage E, Gisselbrecht C, Haioun C et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. Ann Oncol 1993;4:651-656.
9. Milpied N, Deconinck E, Gaillard F et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. New Engl J Med 2004;350:1287-1295.
10. Caballero MD, Perez-Simon JA, Iriondo A et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003;14:140-151.
11. Blayney DW, LeBlanc ML, Grogan T et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003;21:2466-2473.
12. Gregory SA, Case DC Jr, Bosserman L et al. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study. Clin Lymphoma 2003;4:93-98.
13. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439. Erratum in: J Clin Oncol 2003;21:2226.
14. Blayney D, Williams S, Horning S et al. Neupogen (r-metHuG-CSF) ameliorates neutropenia during CHOP therapy. Proc Am Soc Clin Oncol 1992;11:320a.
15. Johnson D, Levitt M, Mason B et al. A phase II trial of filgrastim (r-metHuG-CSF) as an adjunct to cisplatin and etoposide chemotherapy in locally advanced or metastatic non-small cell lung carcinoma. Proc Am Soc Clin Oncol 1993;12:338.
16. Donnelly S, Epstein J, Al-Bussam N et al. Filgrastim experience in diverse nonmyeloid malignancies: a prospective study in community oncology practice. Proc Am Soc Clin Oncol 2003;22:182.
17. Meza LA, Green MD, Hackett JR et al. Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin. Pharmacotherapy 2003;23:1424-1431.
18. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-170.
19. Molineux G, Dexter M. Biology of G-CSF. In: Morstyn G, Dexter TM, eds. Filgrastim (r-metHuG-CSF) in Clinical Practice. New York: Marcel Dekker, Inc., 1994:1-21.
20. Smith GM, Child JA, Cullen MH et al. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (r-metHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group. Hematol Oncol 1996;14:193-201.
21. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
22. Pfreundschuh M, Truemper L, Kloess M et al. 2-weekly vs 3-weekly CHOP with and without etoposide for patients >60 years of age with aggressive non-Hodgkin's lymphoma (NHL): results of the completed NHL-B-2 trial of the DSHNHL. Blood 2002;100:774a.
23. Pfreundschuh M, Truemper L, Schmits R et al. 2-weekly vs 3-weekly CHOP with and without etoposide in young patients with low-risk (low LDH) aggressive non-Hodgkin's lymphoma: results of the completed NHL-B-1 trial of the DSHNHL. Blood 2002;100:92a.
24. Wunderlich A, Kloess M, Reiser M et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2003;14:881-893.
25. Blayney DW, Horning SJ, Bartlett NL. Dose intensification of cyclophosphamide and doxorubicin with adjunctive filgrastim (rG-CSF) in intermediate grade lymphoma. Proceedings of the Fifth International Congress on Malignant Lymphomas, Lugano, Switzerland, June 9-12, 1993.